DaVita HealthCare Partners Inc. (NYSE:DVA) was the recipient of a significant growth in short interest during the month of August. As of August 31st, there was short interest totalling 3,638,958 shares, a growth of 35.9% from the August 15th total of 2,678,130 shares. Approximately 1.8% of the company’s shares are short sold. Based on an average daily volume of 2,437,495 shares, the short-interest ratio is presently 1.5 days.

DaVita HealthCare Partners (NYSE:DVA) opened at 65.83 on Thursday. DaVita HealthCare Partners has a 1-year low of $61.36 and a 1-year high of $78.94. The firm’s 50-day moving average is $66.83 and its 200-day moving average is $73.13. The company has a market capitalization of $13.62 billion, a P/E ratio of 38.30 and a beta of 1.07.

DaVita HealthCare Partners (NYSE:DVA) last posted its quarterly earnings results on Monday, August 8th. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.98 by $0.03. The business earned $3.72 billion during the quarter, compared to analysts’ expectations of $3.67 billion. DaVita HealthCare Partners had a net margin of 2.51% and a return on equity of 16.48%. The firm’s quarterly revenue was up 8.2% compared to the same quarter last year. During the same period last year, the company posted $0.95 earnings per share. Equities research analysts predict that DaVita HealthCare Partners will post $3.76 EPS for the current year.

In related news, insider Jeanine Marie Jiganti sold 4,620 shares of the company’s stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $77.45, for a total transaction of $357,819.00. Following the completion of the transaction, the insider now owns 7,590 shares of the company’s stock, valued at $587,845.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Michael David Staffieri sold 20,262 shares of the company’s stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $73.09, for a total transaction of $1,480,949.58. Following the transaction, the chief operating officer now directly owns 52,279 shares of the company’s stock, valued at approximately $3,821,072.11. The disclosure for this sale can be found here. Corporate insiders own 2.10% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC boosted its stake in DaVita HealthCare Partners by 1.0% in the first quarter. Geode Capital Management LLC now owns 1,417,807 shares of the company’s stock valued at $103,840,000 after buying an additional 13,776 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its stake in DaVita HealthCare Partners by 19.7% in the second quarter. State Board of Administration of Florida Retirement System now owns 277,939 shares of the company’s stock worth $21,490,000 after buying an additional 45,749 shares during the period. ING Groep NV acquired a new stake in DaVita HealthCare Partners during the first quarter worth about $278,000. Arizona State Retirement System boosted its stake in DaVita HealthCare Partners by 0.6% in the first quarter. Arizona State Retirement System now owns 99,086 shares of the company’s stock worth $7,271,000 after buying an additional 600 shares during the period. Finally, AMP Capital Investors Ltd boosted its stake in DaVita HealthCare Partners by 1.5% in the first quarter. AMP Capital Investors Ltd now owns 53,733 shares of the company’s stock worth $3,924,000 after buying an additional 800 shares during the period. Institutional investors and hedge funds own 83.55% of the company’s stock.

Several equities analysts recently commented on DVA shares. Wells Fargo & Co. reaffirmed a “buy” rating on shares of DaVita HealthCare Partners in a research report on Saturday, June 4th. Zacks Investment Research raised shares of DaVita HealthCare Partners from a “hold” rating to a “buy” rating and set a $87.00 price target for the company in a research report on Tuesday, July 5th. JPMorgan Chase & Co. upped their price target on shares of DaVita HealthCare Partners from $74.00 to $75.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 9th. TheStreet lowered shares of DaVita HealthCare Partners from a “buy” rating to a “hold” rating in a research report on Monday, August 8th. Finally, Citigroup Inc. initiated coverage on shares of DaVita HealthCare Partners in a research report on Tuesday, September 6th. They issued a “neutral” rating and a $71.00 price objective for the company. One analyst has rated the stock with a sell rating, eight have issued a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $76.36.

About DaVita HealthCare Partners

DaVita HealthCare Partners Inc is a provider of kidney care services. The Company operates Kidney Care division and HealthCare Partners (HCP) division. Its segments include U.S. dialysis and related lab services, HCP and Other-Ancillary services and strategic initiatives. Its Kidney Care division is a provider of dialysis services in the United States, treating patients with chronic kidney failure and end stage renal disease (ESRD).

5 Day Chart for NYSE:DVA

Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.